AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19186971
Drug: Non-submerged implants
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-submerged implants
Trial: 19186971
Drug: Submerged implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submerged implants
Trial: 17593904
Drug: Fructose beverage
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose beverage (50 g)
Trial: 17593904
Drug: Glucose beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose beverage (50 g)
Trial: 17593904
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein beverage (50 g)
Trial: 14999213
Drug: Biofeedback treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback treatment (6 sessions of abdominal breath training, heart and respiratory physiologic feedback, daily breathing practice)
Trial: 9459398
Drug: oral cefixime
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral cefixime
Trial: 9459398
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum IL‐6 values >400 pg/ml
Trial: 23743804
Drug: STITCH2-care (simplified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STITCH2-care (simplified treatment algorithm featuring single-pill combinations)
Trial: 9356764
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (20 g/day plus 4 g/day glucose)
Trial: 9356764
Drug: Placebo (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (24 g/day glucose)
Trial: 3882125
Drug: Isotretinoin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin (40 mg daily for 2 months)
Trial: 3882125
Drug: Etretinate (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etretinate (50 mg daily for 2 months)
Trial: 20357588
Drug: French physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: French physical therapy (PT)
Trial: 12454831
Drug: PAC7 (pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAC7 (pantoprazole 40 mg, amoxicillin 1000 mg, clarithromycin 500 mg, all twice daily for 7 days)
Trial: 12454831
Drug: PBTM7 (pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBTM7 (pantoprazole 40 mg twice daily, bismuth subcitrate 108 mg, tetracycline 500 mg, both 4 times daily, metronidazole 200 mg 3 times daily and 400 mg at night for 7 days)
Trial: 12454831
Drug: BTM14 (bismuth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTM14 (bismuth subcitrate 108 mg and tetracycline 500 mg, both 4 times daily, metronidazole 200 mg 3 times daily and 400 mg at night for 14 days)
Trial: 10037123
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma from whole-blood preparation, adjusted to 10 x 10(9) platelets per mL
Trial: 10037123
Drug: Platelets collected
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelets collected by apheresis, adjusted to 20 x 10(9) platelets per mL
Trial: 1606996
Drug: Oxazepam 20
RxNorm normalized name: oxazepam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam 20 mg
Trial: 1606996
Drug: Oxazepam 40
RxNorm normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxazepam 40 mg
Trial: 8748394
Drug: Oxazepam (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam (both doses)
Trial: 20511163
Drug: Weight-based, dose-adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based, dose-adjusted filgrastim beginning on day 1 (arm B)
Trial: 21346616
Drug: Quetiapine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 600 mg/d
Trial: 17110817
Drug: Quetiapine 300
RxNorm normalized name: quetiapine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 300 mg/d
Trial: 19956459
Drug: Quetiapine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (both doses)
Trial: 23499726
Drug: Octreotide monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide monotherapy (octreotide 40 mg every 4 weeks)
Trial: 18095028
Drug: Topical sucralfate
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical sucralfate cream
Trial: 8616014
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three treatment arms (FLAC + PIXY321, FLAC + GM‐CSF, FLAC without cytokine)
Trial: 26836730
Drug: Acetazolamide (500-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (500-1000 mg, twice daily)
Trial: 30791951
Drug: Daily breakfast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily breakfast consumption
Trial: 17215188
Drug: NaFeEDTA (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaFeEDTA (20 mg Fe/kg)
Trial: 17215188
Drug: FeSO4 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FeSO4 (30 mg Fe/kg)
Trial: 11730828
Drug: Combined hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormone replacement therapy (2 mg of estradiol combined with 1 mg of norethisterone acetate daily)
Trial: 9143862
Drug: Celiprolol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (2 times 0.5 mg.kg‐1)
Trial: 18626783
Drug: Intraurethral 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraurethral 30 ml of 2% lidocaine jelly
Trial: 18626783
Drug: Intraurethral 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraurethral 30 ml of neutral jelly
Trial: 16230677
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (CCRT) with oxaliplatin 70 mg/m2 weekly for six doses
Trial: 24119807
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (L)
Trial: 19411792
Drug: Health education
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health education program using problem-based learning, 5 weekly sessions, 100-120 min/session
Trial: 18060072
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of UK-39 and AMA49-C1 loaded virosomes
Trial: 9059563
Drug: Pamidronate therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate therapy (150 mg/day) for 3 years
Trial: 9059563
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of pamidronate therapy for 12 months
Trial: 9059563
Drug: Post-discontinuation BMD
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-discontinuation BMD measurement after 1 year
Trial: 8880076
Drug: Moclobemide 300
RxNorm normalized name: moclobemide 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 300 mg
Trial: 9663810
Drug: Moclobemide 450
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 450 mg
Trial: 11195257
Drug: Moclobemide 600
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 600 mg
Trial: 4054700
Drug: L-dopa (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa (500 mg)
Trial: 4054700
Drug: L-dopa (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa (100 mg) plus carbidopa (35 mg) after pretreatment with carbidopa (50 mg every six hours for four doses)
Trial: 18398147
Drug: Toremifene (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene (80 mg/d)
Trial: 1543819
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg am
Trial: 1782306
Drug: Famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg nocte
Trial: 31384310
Drug: Glibenclamide 5
RxNorm normalized name: glibenclamide 5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide 5 mg/day
Trial: 27028957
Drug: Somatostatin analog
RxNorm normalized name: Somatostatin analog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin analog (SSA) therapy
Trial: 27028957
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no SSA therapy)
Trial: 23681906
Drug: Inhaled dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled dual release ciprofloxacin (DRCFI)
Trial: 20492710
Drug: Gold+Lutein (Wyeth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold+Lutein (Wyeth S‐26 Gold fortified with lutein at 200 mcg/l)
Trial: 10849523
Drug: Roquinimex 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roquinimex 0.2 mg/kg body weight, twice weekly for 2 years
Trial: 9203426
Drug: Higher-dose amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher-dose amphotericin B (0.7 mg/kg/day) plus flucytosine (100 mg/kg/day) for two weeks
Trial: 9203426
Drug: Higher-dose amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher-dose amphotericin B (0.7 mg/kg/day) alone
Trial: 9203426
Drug: Fluconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (400 mg/day) for eight weeks
Trial: 20845628
Drug: Ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg kg-1 intravenously 20 min before completion of surgery
Trial: 19014842
Drug: Amoxicillin/clavulanate (80-90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (80-90 mg/kg amoxicillin daily) for 14 days
Trial: 12855319
Drug: Dexketoprofen trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen trometamol 25 mg q.i.d.
Trial: 25363203
Drug: CTG +
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CTG + L (Connective Tissue Graft with Low-Level Laser Therapy)
Trial: 25363203
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (CTG and CTG + L)
Trial: 23458226
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg tablet under fed conditions
Trial: 23458226
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg tablet under fed conditions
Trial: 23458226
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg tablet under fed conditions
Trial: 23458226
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg tablet under fasting conditions
Trial: 23458226
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg tablet under fasting conditions
Trial: 23458226
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg oral suspension under fasting conditions
Trial: 23458226
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg oral suspension under fasting and fed conditions
Trial: 20112484
Drug: Yiqi Bushen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqi Bushen Koufuye combined with chemotherapy
Trial: 3524465
Drug: Chemotherapy (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (control group)
Trial: 16675812
Drug: Rectal quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal quinine (20 mg/kg diluted to 30 mg/ml in water solution)
Trial: 16675812
Drug: Intramuscular quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular quinine (12.5 mg/kg)
Trial: 15065610
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 88 microg twice daily
Trial: 7604802
Drug: Fluvastatin 20
RxNorm normalized name: fluvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 20 mg/day plus cholestyramine 4 g/day
Trial: 7604802
Drug: Fluvastatin 20
RxNorm normalized name: fluvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 20 mg/day plus cholestyramine 8 g/day
Trial: 7604802
Drug: Fluvastatin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin plus cholestyramine (all doses)
Trial: 345423
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of cephradine orally twice daily (b.i.d.)
Trial: 345423
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of cephradine given 4 times a day (q.i.d.)
Trial: 24615239
Drug: Caffeine-containing energy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine-containing energy drink (3 mg of caffeine/kg)
Trial: 17468493
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: BIS 45(5), remifentanil 1 ng ml(‐1)
Trial: 17468493
Drug: Group 3:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3: BIS 45(5), remifentanil 4 ng ml(‐1)
Trial: 12469979
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg modified release capsule of mebeverine
Trial: 12469979
Drug: 135 mg
RxNorm normalized name: cocaine 135 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 135 mg plain tablet of mebeverine
Trial: 9306300
Drug: Dopamine receptor
RxNorm normalized name: Dopamine receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine receptor antagonists (haloperidol or fluphenazine)
Trial: 3537635
Drug: guanfacine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guanfacine (0.5 mg/day)
Trial: 30135020
Drug: Dose modification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose modification (adjustment or treatment delay)
Trial: 30135020
Drug: Granulocyte colony
RxNorm normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Granulocyte colony stimulating factor (G‐CSF) use in dose-modified patients
Trial: 30135020
Drug: No dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No dose modification (referent group)
Trial: 25460150
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release tablet Sirdalud® (control).
Trial: 20172704
Drug: Ipratropium bromide/albuterol
RxNorm normalized name: ipratropium bromide/albuterol sulfate 0.5 mg-2.5 mg/2.5 mL INHALATION VIAL, NEBULIZER (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide/albuterol Respimat inhaler (20/100mcg)
Trial: 8669601
Drug: Cisapride 20
RxNorm normalized name: cisapride 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 20 mg plus diazepam 10 mg
Trial: 28884737
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy (reflexotherapy) combined with pharmacotherapy and psychologist's recommendations
Trial: 28884737
Drug: Medication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication therapy and psychotherapy without acupuncture
Trial: 25886327
Drug: Group FPM
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group FPM (IV fortwin 0.3 mg/kg over 1 min + IV midazolam 0.04 mg/kg + IV phenergan 12.5 mg)
Trial: 25886327
Drug: Group KM
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group KM (IV ketamine 0.3 mg/kg over 1 min + IV midazolam 0.04 mg/kg)
Trial: 19765321
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine gluconate applied once or twice a day
Trial: 17534818
Drug: Topical betaxolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betaxolol HCl 0.25% suspension
Trial: 17534818
Drug: Topical betaxolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betaxolol HCl 0.50% solution
Trial: 9725482
Drug: Two suppositories
RxNorm normalized name: potassium bitartrate / sodium bicarbonate Rectal Suppository [Ceo-Two]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two suppositories of 500 mg
Trial: 9725482
Drug: Two tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of 500 mg
Trial: 31555824
Drug: PfSPZ vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ vaccine (doses: 1.35 × 10^5, 2.7 × 10^5, 4.5 × 10^5, 9.0 × 10^5, and 1.8 × 10^6) administered by direct venous inoculation (DVI)
Trial: 31555824
Drug: PfSPZ vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ vaccine (doses: 9.0 × 10^5 and 1.8 × 10^6)
Trial: 28391437
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (IV ferric gluconate 125 mg weekly for 8 weeks)
Trial: 28391437
Drug: Oral sucrosomial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sucrosomial iron (30 mg daily for 8 weeks)
Trial: 28391437
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (IV ferric gluconate)
Trial: 24186595
Drug: Exenatide 10
RxNorm normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 10 μg BID (n = 40)
Trial: 24186595
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine once daily (n = 40)
Trial: 21990399
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with residual disease after chemotherapy
Trial: 18434722
Drug: Buffered phosphate
RxNorm normalized name: PHOSPHATE BUFFERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered phosphate solution (placebo control, n = 12)
Trial: 17075117
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 plus fluorouracil 750 mg/m2/d (DCF)
Trial: 17075117
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 plus fluorouracil 1,000 mg/m2/d (CF)
Trial: 10901181
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (doses slowly escalating to achieve hematocrit of 42+/‐3%)
Trial: 8837186
Drug: Single-shot spinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-shot spinal anesthesia with 1% hyperbaric bupivacaine (0.27 mg/kg)
Trial: 8837186
Drug: Incremental 5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incremental 5-mg bolus of 1% hyperbaric bupivacaine via a subarachnoid 32-gauge microcatheter every 10 minutes
Trial: 1570381
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg oral diazepam
Trial: 26616644
Drug: Oral chloral
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chloral hydrate 70 mg · kg(‐1)
Trial: 25238873
Drug: 4 weekly
RxNorm normalized name: TOBI Podhaler Kit, 4 Weekly Packs, each including 56 capsules (7 Blister Cards of 8 Capsules)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weekly regular early specialist symptom control care
Trial: 21890793
Drug: Usual community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual community treatment
Trial: 21890793
Drug: Cumulative stimulant
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative stimulant exposure
Trial: 30618445
Drug: Two-dose sulphadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose sulphadoxine-pyrimethamine (SP)
Trial: 7864420
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg of mivacurium after 1.0 mg/kg of succinylcholine
Trial: 7864420
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg of mivacurium without succinylcholine
Trial: 7262517
Drug: Slow duodenal
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow duodenal perfusion rate of [14C]PEG in saline (0.25 ml/min)
Trial: 7262517
Drug: Fast duodenal
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast duodenal perfusion rate (3.0 ml/min)
Trial: 28110628
Drug: Sublingual glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual glyceryl trinitrate (800 µg)